Page 9 - Probe Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ARTMS Inc. (ARTMS) is excited to announce Health Canada’s marketing approval of cyclotron produced technetium-99m ( 99mTc) for clinical use. For the Health Canada submission, ARTMS provided technical expertise and the solid targets required for production to a Canadian consortium consisting of BC Cancer, TRIUMF, Lawson Health Research and the Centre for Probe Development and Commercialization. The process was approved by Health Canada on November 26, 2020 and is being deployed immediately. “The Nuclear Medicine community and our patients have seen multiple supply chain challenges with 99...

December 22, 2020 -- Medical isotope developer ARTMS of British Columbia, Canada, announced that its cyclotron-produced technetium-99m (Tc-99m) radioisotope is being shipped commercially following approval on November 26 for clinical use by Health Canada. The application for approval by Health Canada was supported by a joint filing from ARTMS, BC Cancer, the TRIUMF particle accelerator center in Canada, Lawson Health Research, and the Centre for Probe Development and Commercialization. In a statement about the approval, ARTMS said that its cyclotron-based technology provides a badly needed al...